{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:54:12Z","timestamp":1772135652567,"version":"3.50.1"},"reference-count":85,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:00:00Z","timestamp":1640304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21fk0108607h"],"award-info":[{"award-number":["JP21fk0108607h"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21fk0108129h"],"award-info":[{"award-number":["JP21fk0108129h"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Mycobacteriosis is mainly caused by two groups of species: Mycobacterium tuberculosis and non-tuberculosis mycobacteria (NTM). The pathogens cause not only respiratory infections, but also general diseases. The common problem in these pathogens as of today is drug resistance. Tuberculosis (TB) is a major public health concern. A major challenge in the treatment of TB is anti-mycobacterial drug resistance (AMR), including multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Recently, the success rate of the treatment of drug-resistant tuberculosis (DR-TB) has improved significantly with the introduction of new and repurposed drugs, especially in industrialized countries such as Japan. However, long-term treatment and the adverse events associated with the treatment of DR-TB are still problematic. To solve these problems, optimal treatment regimens designed\/tailor-made for each patient are necessary, regardless of the location in the world. In contrast to TB, NTM infections are environmentally oriented. Mycobacterium avium-intracellulare complex (MAC) and Mycobacterium abscessus species (MABS) are the major causes of NTM infections in Japan. These bacteria are naturally resistant to a wide variation of antimicrobial agents. Macrolides, represented by clarithromycin (CLR) and amikacin (AMK), show relatively good correlation with treatment success. However, the efficacies of potential drugs for the treatment of macrolide-resistant MAC and MABS are currently under evaluation. Thus, it is particularly difficult to construct an effective treatment regimen for macrolide-resistant MAC and MABS. AMR in NTM infections are rather serious in Japan, even when compared with challenges associated with DR-TB. Given the AMR problems in TB and NTM, the appropriate use of drugs based on accurate drug susceptibility testing and the development of new compounds\/regimens that are strongly bactericidal in a short-time course will be highly expected.<\/jats:p>","DOI":"10.3390\/antibiotics11010019","type":"journal-article","created":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T08:38:46Z","timestamp":1640335126000},"page":"19","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Anti-Mycobacterial Drug Resistance in Japan: How to Approach This Problem?"],"prefix":"10.3390","volume":"11","author":[{"given":"Keisuke","family":"Kamada","sequence":"first","affiliation":[{"name":"Department of Mycobacterium Reference and Research, the Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo 204-8533, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2288-077X","authenticated-orcid":false,"given":"Satoshi","family":"Mitarai","sequence":"additional","affiliation":[{"name":"Department of Mycobacterium Reference and Research, the Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo 204-8533, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,24]]},"reference":[{"key":"ref_1","unstructured":"Tuberculosis Surveillance Center, Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association (2021, December 13). TUBERCULOSIS IN JAPAN ANNUAL REPORT 2021. Available online: https:\/\/jata-ekigaku.jp\/wp-content\/uploads\/2021\/11\/TB-in-Japan_2021.pdf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.3201\/eid2206.151086","article-title":"Epidemiology of Pulmonary Nontuberculous Mycobacterial Disease, Japan","volume":"22","author":"Namkoong","year":"2016","journal-title":"Emerg. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1513\/AnnalsATS.201303-067OC","article-title":"A steady increase in nontuberculous mycobacteriosis mortality and estimated prevalence in Japan","volume":"11","author":"Morimoto","year":"2014","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1513\/AnnalsATS.201607-573OC","article-title":"A Laboratory-based Analysis of Nontuberculous Mycobacterial Lung Disease in Japan from 2012 to 2013","volume":"14","author":"Morimoto","year":"2017","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.1038\/s41598-021-84537-7","article-title":"Geographical distribution and regional differences in 532 clinical isolates of rapidly growing mycobacterial species in Japan","volume":"11","author":"Kamada","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1900250","DOI":"10.1183\/13993003.00250-2019","article-title":"Non-tuberculous mycobacterial pulmonary disease","volume":"54","author":"Cowman","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1183\/09031936.00149212","article-title":"The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: An NTM-NET collaborative study","volume":"42","author":"Hoefsloot","year":"2013","journal-title":"Eur. Respir. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1164\/rccm.201909-1874ST","article-title":"Treatment of Drug-Resistant Tuberculosis. An Official ATS\/CDC\/ERS\/IDSA Clinical Practice Guideline","volume":"200","author":"Nahid","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_10","unstructured":"World Health Organization (2021, November 17). WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment\u2014Drug-Resistant Tuberculosis Treatment. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240007048."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2003300","DOI":"10.1183\/13993003.03300-2020","article-title":"World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update","volume":"57","author":"Mirzayev","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_12","unstructured":"The Treatment Committee of the Japanese Society for Tuberculosis and Non-Tuberculous Mycobacteriosis (2020). Approach to MDR TB treatment in Japan. Kekkaku, 95, 79\u201384. (In Japanese)."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of Highly Drug-Resistant Pulmonary Tubserculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2100361","DOI":"10.1183\/13993003.00361-2021","article-title":"New definitions of pre-extensively and extensively drug-resistant tuberculosis: Update from the World Health Organization","volume":"57","author":"Viney","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/cid\/ciaa1125","article-title":"Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS\/ERS\/ESCMID\/IDSA Clinical Practice Guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.chest.2020.10.031","article-title":"Managing Mycobacterium avium Complex Lung Disease with a Little Help from My Friend","volume":"159","author":"Griffith","year":"2021","journal-title":"Chest"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.chest.2018.01.024","article-title":"Microbiologic Outcome of Interventions Against Mycobacterium avium Complex Pulmonary Disease: A Systematic Review","volume":"153","author":"Diel","year":"2018","journal-title":"Chest"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jiac.2017.01.007","article-title":"The clinical efficacy of a clarithromycin-based regimen for Mycobacterium avium complex disease: A nationwide post-marketing study","volume":"23","author":"Kadota","year":"2017","journal-title":"J. Infect. Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.chest.2019.12.016","article-title":"Treatment Duration and Disease Recurrence Following the Successful Treatment of Patients with Mycobacterium avium Complex Lung Disease","volume":"157","author":"Furuuchi","year":"2020","journal-title":"Chest"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1164\/rccm.200603-450OC","article-title":"Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease","volume":"174","author":"Griffith","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1513\/AnnalsATS.201604-246OC","article-title":"Macrolide-Resistant Mycobacterium avium Complex Lung Disease: Analysis of 102 Consecutive Cases","volume":"13","author":"Morimoto","year":"2016","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","article-title":"Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study","volume":"198","author":"Griffith","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1513\/AnnalsATS.202008-925OC","article-title":"Amikacin Liposome Inhalation Suspension for Mycobacterium avium Complex Lung Disease: A 12-Month Open-Label Extension Clinical Trial","volume":"18","author":"Winthrop","year":"2021","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.chest.2017.04.175","article-title":"Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection","volume":"152","author":"Martiniano","year":"2017","journal-title":"Chest"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.chest.2020.07.040","article-title":"Minimal Inhibitory Concentration of Clofazimine Among Clinical Isolates of Nontuberculous Mycobacteria and Its Impact on Treatment Outcome","volume":"159","author":"Kwak","year":"2021","journal-title":"Chest"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"ofz108","DOI":"10.1093\/ofid\/ofz108","article-title":"Sitafloxacin-Containing Regimen for the Treatment of Refractory Mycobacterium avium Complex Lung Disease","volume":"6","author":"Asakura","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e01206","DOI":"10.1128\/AAC.01206-17","article-title":"Systematic Review and Meta-analyses of the Effect of Chemotherapy on Pulmonary Mycobacterium abscessus Outcomes and Disease Recurrence","volume":"61","author":"Pasipanodya","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1801991","DOI":"10.1183\/13993003.01991-2018","article-title":"M ycobacterium abscessus pulmonary disease: Individual patient data meta-analysis","volume":"54","author":"Kwak","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.3389\/fmicb.2019.01977","article-title":"Clinical Efficacy and Adverse Effects of Antibiotics Used to Treat Mycobacterium abscessus Pulmonary Disease","volume":"10","author":"Chen","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"ofab215","DOI":"10.1093\/ofid\/ofab215","article-title":"Impact of Susceptibility to Injectable Antibiotics on the Treatment Outcomes of Mycobacterium abscessus Pulmonary Disease","volume":"8","author":"Park","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_32","unstructured":"Clinical and Laboratory Standards Institute (2021, December 21). Susceptibility Testing of Mycobacteria, Nocardiae and Other Aerobic Actinomycetes. Approved Standard. CLSI Document M24 3rd Edition (CLSI 2018). Available online: https:\/\/clsi.org\/standards\/products\/microbiology\/documents\/m24\/."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3201\/eid2203.151643","article-title":"Leveraging Advances in Tuberculosis Diagnosis and Treatment to Address Nontuberculous Mycobacterial Disease","volume":"22","author":"Raju","year":"2016","journal-title":"Emerg Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"985","DOI":"10.3201\/eid2703.204418","article-title":"Limited Capability for Testing Mycobacterium tuberculosis for Susceptibility to New Drugs","volume":"27","author":"Farooq","year":"2021","journal-title":"Emerg. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/0140-6736(93)90417-F","article-title":"Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis","volume":"341","author":"Telenti","year":"1993","journal-title":"Lancet"},{"key":"ref_36","unstructured":"Global Laboratory Initiative (2021, November 17). GLI Model TB Diagnostic Algorithms. Available online: https:\/\/stoptb.org\/wg\/gli\/assets\/documents\/gli_algorithms.pdf."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/jac\/dkaa136","article-title":"Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid","volume":"75","author":"Kadura","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2001796","DOI":"10.1183\/13993003.01796-2020","article-title":"Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex-MycTB","volume":"57","author":"Feuerriegel","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Smith, C., Halse, T.A., Shea, J., Modestil, H., Fowler, R.C., Musser, K.A., Escuyer, V., and Lapierre, P. (2020). Assessing Nanopore Sequencing for Clinical Diagnostics: A Comparison of Next-Generation Sequencing (NGS) Methods for Mycobacterium tuberculosis. J. Clin. Microbiol., 59.","DOI":"10.1128\/JCM.00583-20"},{"key":"ref_40","unstructured":"Clinical and Laboratory Standards Institute (2021, December 21). Susceptibility Testing of Mycobacteria, Nocardiae and Other Aerobic Actinomycetes. Approved Standard. CLSI Document M62 (CLSI 2018). Available online: https:\/\/clsi.org\/standards\/products\/microbiology\/documents\/m24-supplement\/."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.1128\/AAC.01240-16","article-title":"Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease","volume":"60","author":"Moon","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1128\/JCM.01612-13","article-title":"In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates","volume":"51","author":"Iakhiaeva","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1348-0421.2010.00221.x","article-title":"Mycobacterium massiliense is differentiated from Mycobacterium abscessus and Mycobacterium bolletii by erythromycin ribosome methyltransferase gene (erm) and clarithromycin susceptibility patterns","volume":"54","author":"Kim","year":"2010","journal-title":"Microbiol. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1128\/JCM.02950-14","article-title":"Utility of sequencing the erm(41) gene in isolates of Mycobacterium abscessus subsp. abscessus with low and intermediate clarithromycin MICs","volume":"53","author":"Vasireddy","year":"2015","journal-title":"J. Clin. Microbiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1128\/AAC.40.7.1676","article-title":"Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus","volume":"40","author":"Wallace","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1093\/jac\/dkw130","article-title":"Standardized interpretation of antibiotic susceptibility testing and resistance genotyping for Mycobacterium abscessus with regard to subspecies and erm41 sequevar","volume":"71","author":"Mougari","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"6108","DOI":"10.1038\/s41598-021-85721-5","article-title":"Association between 16S rRNA gene mutations and susceptibility to amikacin in Mycobacterium avium Complex and Mycobacterium abscessus clinical isolates","volume":"11","author":"Kim","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Tuberculosis Research Committee (RYOKEN), Tokyo, Japan (2015). Nationwide survey of anti-tuberculosis drug resistance in Japan. Int. J. Tuberc. Lung Dis., 19, 157\u2013162.","DOI":"10.5588\/ijtld.13.0905"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Kawatsu, L., Uchimura, K., Izumi, K., Ohkado, A., and Yoshiyama, T. (2018). Treatment outcome of multidrug-resistant tuberculosis in Japan - the first cross-sectional study of Japan tuberculosis surveillance data. BMC Infect. Dis., 18.","DOI":"10.1186\/s12879-018-3353-9"},{"key":"ref_50","unstructured":"(2007). Drug-resistant Mycobacterium tuberculosis in Japan: A nationwide survey, 2002. Int. J. Tuberc. Lung Dis., 11, 1129\u20131135."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.5588\/ijtld.18.0822","article-title":"Linezolid for the treatment of extensively drug-resistant tuberculosis: A systematic review and meta-analysis","volume":"23","author":"Lifan","year":"2019","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_52","unstructured":"World Health Organization (2021, November 17). Position Statement on Innovative Clinical Trial Design for Development of New TB Treatments. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240030800."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Kawasaki, M., Echiverri, C., Raymond, L., Cadena, E., Reside, E., Gler, M.T., Oda, T., Ito, R., Higashiyama, R., and Katsuragi, K. (2019). Lipoarabinomannan in sputum to detect bacterial load and treatment response in patients with pulmonary tuberculosis: Analytic validation and evaluation in two cohorts. PLoS Med., 16.","DOI":"10.1371\/journal.pmed.1002780"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ijid.2020.04.059","article-title":"Ultrasensitive enzyme-linked immunosorbent assay for the detection of MPT64 secretory antigen to evaluate Mycobacterium tuberculosis viability in sputum","volume":"96","author":"Sakashita","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1164\/rccm.201107-1203OC","article-title":"Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease","volume":"185","author":"Hayashi","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e008058","DOI":"10.1136\/bmjopen-2015-008058","article-title":"Retrospective study of the predictors of mortality and radiographic deterioration in 782 patients with nodular\/bronchiectatic Mycobacterium avium complex lung disease","volume":"5","author":"Gochi","year":"2015","journal-title":"BMJ. Open"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Kadota, T., Matsui, H., Hirose, T., Suzuki, J., Saito, M., Akaba, T., Kobayashi, K., Akashi, S., Kawashima, M., and Tamura, A. (2016). Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease. BMC Infect. Dis., 16.","DOI":"10.1186\/s12879-016-1384-7"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"106025","DOI":"10.1016\/j.rmed.2020.106025","article-title":"Macrolide resistant Mycobacterium avium complex pulmonary disease following clarithromycin and ethambutol combination therapy","volume":"169","author":"Ito","year":"2020","journal-title":"Respir. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.4951","article-title":"A survey of clarithromycin monotherapy and long-term administration of ethambutol for patients with MAC lung disease in Japan: A retrospective cohort study using the database of health insurance claims","volume":"29","author":"Iwao","year":"2020","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jiac.2019.05.028","article-title":"Moxifloxacin resistance and genotyping of Mycobacterium avium and Mycobacterium intracellulare isolates in Japan","volume":"25","author":"Yamaba","year":"2019","journal-title":"J. Infect. Chemother."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1128\/JCM.41.2.627-631.2003","article-title":"Multisite reproducibility of results obtained by two broth dilution methods for susceptibility testing of Mycobacterium avium complex","volume":"41","author":"Woods","year":"2003","journal-title":"J. Clin. Microbiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.rmed.2018.10.012","article-title":"Clinico-microbiological analysis of 121 patients with pulmonary Mycobacteroides abscessus complex disease in Japan - An NTM-JRC study with RIT","volume":"145","author":"Morimoto","year":"2018","journal-title":"Respir. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s10096-020-04026-z","article-title":"Clinical risk factors related to treatment failure in Mycobacterium abscessus lung disease","volume":"40","author":"Fujiwara","year":"2021","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jiac.2018.10.010","article-title":"Antimicrobial susceptibility testing of Mycobacteroides (Mycobacterium) abscessus complex, Mycolicibacterium (Mycobacterium) fortuitum, and Mycobacteroides (Mycobacterium) chelonae","volume":"25","author":"Aono","year":"2019","journal-title":"J. Infect. Chemother"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"12208","DOI":"10.1038\/s41598-021-91757-4","article-title":"Nationwide surveillance of antimicrobial susceptibility of 509 rapidly growing mycobacteria strains isolated from clinical specimens in Japan","volume":"11","author":"Kamada","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Kadota, N., Shinohara, T., Hino, H., Goda, Y., Murase, Y., Mitarai, S., and Ogushi, F. (2019). Mycobacterium abscessus ssp. abscessus infection progressing to empyema from vertebral osteomyelitis in an immunocompetent patient without pulmonary disease: A case report. BMC Pulm. Med., 19.","DOI":"10.1186\/s12890-019-0860-4"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e924642","DOI":"10.12659\/AJCR.924642","article-title":"Mycobacterium abscessus Associated Peritonitis with CAPD Successfully Treated Using a Linezolid and Tedizolid Containing Regimen Suggested Immunomodulatory Effects","volume":"21","author":"Seki","year":"2020","journal-title":"Am. J. Case Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/med.21602","article-title":"An overview of new antitubercular drugs, drug candidates, and their targets","volume":"40","author":"Bahuguna","year":"2020","journal-title":"Med. Res. Rev."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1128\/AAC.43.5.1189","article-title":"Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model","volume":"43","author":"Cynamon","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1164\/rccm.200904-0611OC","article-title":"Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis","volume":"180","author":"Williams","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Wallis, R.S., Dawson, R., Friedrich, S.O., Venter, A., Paige, D., Zhu, T., Silvia, A., Gobey, J., Ellery, C., and Zhang, Y. (2014). Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0094462"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e0058321","DOI":"10.1128\/AAC.00583-21","article-title":"Comparative Analysis of Pharmacodynamics in the C3HeB\/FeJ Mouse Tuberculosis Model for DprE1 Inhibitors TBA-7371, PBTZ169, and OPC-167832","volume":"65","author":"Robertson","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Hariguchi, N., Chen, X., Hayashi, Y., Kawano, Y., Fujiwara, M., Matsuba, M., Shimizu, H., Ohba, Y., Nakamura, I., and Kitamoto, R. (2020). OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor. Antimicrob. Agents Chemother., 64.","DOI":"10.1128\/AAC.02020-19"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.bmc.2019.02.026","article-title":"3,5-Dialkoxypyridine analogues of bedaquiline are potent antituberculosis agents with minimal inhibition of the hERG channel","volume":"27","author":"Sutherland","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Xu, J., Converse, P.J., Upton, A.M., Mdluli, K., Fotouhi, N., and Nuermberger, E.L. (2021). Comparative Efficacy of the Novel Diarylquinoline TBAJ-587 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis. Antimicrob. Agents Chemother., 65.","DOI":"10.1128\/AAC.02418-20"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e0141221","DOI":"10.1128\/AAC.01412-21","article-title":"Comparative efficacy of the novel diarylquinoline TBAJ-876 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis","volume":"65","author":"Almeida","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Kim, D.H., Jhun, B.W., Moon, S.M., Kim, S.Y., Jeon, K., Kwon, O.J., Huh, H.J., Lee, N.Y., Shin, S.J., and Daley, C.L. (2019). In Vitro Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.00665-19"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1378\/chest.14-2764","article-title":"Preliminary Results of Bedaquiline as Salvage Therapy for Patients with Nontuberculous Mycobacterial Lung Disease","volume":"148","author":"Philley","year":"2015","journal-title":"Chest"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1128\/JCM.02087-16","article-title":"Emergence of mmpT5 Variants during Bedaquiline Treatment of Mycobacterium intracellulare Lung Disease","volume":"55","author":"Alexander","year":"2017","journal-title":"J. Clin. Microbiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1128\/AAC.04347-14","article-title":"A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections","volume":"59","author":"Locher","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Pennings, L.J., Ruth, M.M., Wertheim, H.F.L., and van Ingen, J. (2021). The Benzimidazole SPR719 Shows Promising Concentration-Dependent Activity and Synergy against Nontuberculous Mycobacteria. Antimicrob. Agents Chemother., 65.","DOI":"10.1128\/AAC.02469-20"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/cid\/ciz1014","article-title":"Omadacycline in the Treatment of Mycobacterium abscessus Infection","volume":"71","author":"Madariaga","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1093\/jac\/dkz267","article-title":"Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus","volume":"74","author":"Bax","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Gotfried, M.H., Horn, K., Garrity-Ryan, L., Villano, S., Tzanis, E., Chitra, S., Manley, A., Tanaka, S.K., and Rodvold, K.A. (2017). Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.01135-17"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"ofab002","DOI":"10.1093\/ofid\/ofab002","article-title":"Preliminary, Real-world, Multicenter Experience with Omadacycline for Mycobacterium abscessus Infections","volume":"8","author":"Morrisette","year":"2021","journal-title":"Open Forum Infect. Dis."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/1\/19\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:52:58Z","timestamp":1760169178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/1\/19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,24]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["antibiotics11010019"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics11010019","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,24]]}}}